

# Glenda G Anderson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6800252/publications.pdf>

Version: 2024-02-01

9  
papers

706  
citations

1163117  
8  
h-index

1474206  
9  
g-index

9  
all docs

9  
docs citations

9  
times ranked

1126  
citing authors

#	ARTICLE	IF	CITATIONS
1	Multicenter Validation of a 1,550-Gene Expression Profile for Identification of Tumor Tissue of Origin. <i>Journal of Clinical Oncology</i> , 2009, 27, 2503-2508.	1.6	190
2	Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors. <i>Cancer Cell</i> , 2016, 30, 940-952.	16.8	104
3	A Multicenter Study Directly Comparing the Diagnostic Accuracy of Gene Expression Profiling and Immunohistochemistry for Primary Site Identification in Metastatic Tumors. <i>American Journal of Surgical Pathology</i> , 2013, 37, 1067-1075.	3.7	90
4	Interlaboratory Performance of a Microarray-Based Gene Expression Test to Determine Tissue of Origin in Poorly Differentiated and Undifferentiated Cancers. <i>Journal of Molecular Diagnostics</i> , 2008, 10, 67-77.	2.8	88
5	Determining Tissue of Origin for Metastatic Cancers. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2010, 18, 3-8.	1.2	87
6	Tissue Handling for Genome-Wide Expression Analysis: A Review of the Issues, Evidence, and Opportunities. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 1805-1816.	2.5	84
7	Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, Î²-lapachone. <i>Scientific Reports</i> , 2015, 5, 17066.	3.3	50
8	A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. <i>Blood Advances</i> , 2019, 3, 1837-1847.	5.2	10
9	Reply to G.R. Varadhachary et al. <i>Journal of Clinical Oncology</i> , 2009, 27, e87-e88.	1.6	3